by epdev | May 27, 2022 | Conferences
June 2022, Chicago, Illinois Oral Presentation: Inflammation and Immunology: Feature Company Showcase Poster: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation (PREVLAR)
by epdev | May 27, 2022 | Conferences
May 2022, San Francisco, California Oral Presentation: Inflammation and Immunology: Feature Company Showcase Poster: The ABCs of COVID-19 Related ARDS Treatment Poster: N-VAX, a universal coronavirus vaccine Poster: RRx-001, an NLRP3 inflammasome inhibitor,...
by epdev | May 27, 2022 | 2022, Media & Press Releases
TORREY PINES, CA, May 27, 2022 — EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that data from a...
by epdev | May 10, 2022 | 2022, Media & Press Releases
TORREY PINES, CA, May 10, 2022 — EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has been...
by epdev | Apr 21, 2022 | 2022, Media & Press Releases
Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer TORREY PINES, CA, April 21, 2022 – EpicentRx Inc., a leading-edge immunotherapy company using...
